Bringing the Oncology Community Together

Dr. van den Brink on Adding Ibrutinib to R-CHOP in NHL

Marcel R.M. van den Brink, MD, PhD
Published Online: Wednesday, December 4, 2013
Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Alan N. Houghton Chair, Memorial Sloan-Kettering Cancer Center, discusses a trial being presented at the 2013 ASH Annual Meeting, analyzing the addition of ibrutinib to R-CHOP in patients with non-Hodgkin’s lymphoma (NHL).

Ibrutinib, a promising novel agent that blocks Bruton's tyrosine kinase activity, was analyzed in a phase I study in combination with R-CHOP in treatment-naive patients with CD20-positive B-cell non-Hodgkin’s lymphoma.

According to the abstract, the objective response rate (ORR) for the 15 evaluable patients was 100%, with a 73% complete response (CR) rate. Interim data specifically for the 22 patients with diffuse large B cell lymphoma (DLBCL) also demonstrated a 100% ORR, with a CR rate of 64%.

In the study, the combination of ibrutinib and R-CHOP had an acceptable safety profile. Many of the side effects associated with the treatment were similar to R-CHOP alone, the currently accepted standard of care for patients in this setting.

Related Articles
Role of Radiation Therapy in Hodgkin Lymphoma
Panelists discuss the evolving role of radiation therapy in Hodgkin lymphoma and whether new approaches lessen the long-term toxicity traditionally associated with this treatment modality.
FDA Approves First-Line Ofatumumab for Fludarabine-Ineligble Patients With CLL
The FDA has approved ofatumumab plus chlorambucil for previously untreated patients with chronic lymphocytic leukemia who are considered inappropriate for treatment with fludarabine therapy.
Treatment Landscape for Mantle Cell Lymphoma Continues to Evolve
Lymphoma expert Andre Goy, MD, provides insight into the rapidly changing treatment landscape for patients with mantle cell lymphoma.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.